

RTOG Presentations (cont.)

Tuesday, June 08, 2004

12:00-12:15 pm	 Head and Neck Cancer Chair: Harlan Pinto, MD
(Oral Presentation)	Update of MACH-NC (Meta-Analysis of Chemotherapy in Head & Neck Cancer) database focused on concomitant chemoradiotherapy. Presenter: Jean Bourhis, MD, PhD Abstract No: 5505
355 (Escalators 3 & 4)	



Copyright 2004 American Society of Clinical Oncology
All rights reserved worldwide

All presentation information was extracted from the ASCO Online Pocket Program located at www.asco.org. This program allows you to browse or search for the 2004 Annual Meeting sessions as well as create your own customized itinerary.

* ASCO, the name American Society of Clinical Oncology and the ASCO logo are registered trademarks of the American Society of Clinical Oncology, Inc.

This booklet was created by RTOG Headquarters for the RTOG presenters and members that are attending the 40th ASCO Annual Meeting.

Radiation Therapy Oncology Group

RTOG



The Radiation Therapy Oncology Group, known as RTOG, is a national cancer research organization sponsored and funded by the National Cancer Institute (NCI). It is made up of over 250 leading medical facilities from the United States and Canada. Over the last 25 years the RTOG has played a key role in the development of new treatments for cancer.

For additional information regarding publications, please contact:

RTOG Publication's Assistant

1101 Market Street
Suite 1400
Philadelphia, PA 19107
www.rtog.org




RTOG Presented Abstracts at

40th Annual

ASCO

Meeting

Morial Convention Center



June 5 to June 8, 2004

New Orleans, LA

Radiation Therapy Oncology Group (RTOG) Presentations

Saturday, June 05, 2004

1:00-5:00 pm 

Central Nervous System Tumors

Chair: Michael Prados, MD

(Poster Discussion)

R06 (2nd Floor - Escalators 1 & 2)

A phase II trial of conventional radiation therapy (XRT) plus high dose tamoxifen (TAM) for the treatment of supratentorial glioblastoma multiforme (GBM): RTOG protocol BR-0021.
Presenter: H. I. Robins, MD, PhD
 Poster Number: 20 / Abstract No: 1529

1:00-5:00 pm 

Gastrointestinal (Colorectal) Cancer

(General Poster Session)

Hall A (right half)

Randomized phase II trial of preoperative combined modality chemoradiation for distal rectal cancer.
Presenter: Edith P. Mitchell, MD
 Poster Number: D8 / Abstract No: 3535

Sunday, June 06, 2004

7:45-8:00 am 

Central Nervous System Tumors

Chair: Susan Marina Chang, MD

(Oral Presentation)

R04 (2nd Floor - Escalators 1 & 2)

An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas: Initial report of RTOG 94-02.
Presenter: Gregory Cairncross
 Abstract No: 1500

10:30-10:45 am 

Central Nervous System Tumors

Chair: Susan Marina Chang, MD

(Oral Presentation)

R04 (2nd Floor - Escalators 1 & 2)

Evaluation of expression of DNA repair molecules as a prognostic factor for long-term survivors with glioblastoma multiforme (GBM) treated on RTOG protocols with irradiation and nitrosoureas.
Presenter: Clyde Ford, MD
 Abstract No: 1509

9:30-9:45 am 

Lung Cancer I

Chair: David R. Gandara, MD; Hak Choy, MD

(Oral Presentation)

Hall G

Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633
Presenter: Gary M. Strauss, MD, MPH
 Abstract No: 7019

Sunday, June 06, 2004 (cont.)

1:00-5:00 pm 

Central Nervous System Tumors

(General Poster Session)

Hall A (right half)

An update of phase I data from RTOG 0211: A phase I/II clinical study of gefitinib+ radiation for newly-diagnosed glioblastoma (GBM) patients.
Presenter: Arnab Chakravarti, MD
 Poster Number: D4 / Abstract No: 1571

1:00-5:00 pm 

Head and Neck Cancer

Chair: Dong M. Shin, MD; Lillian L. Siu, MD

(Poster Discussion)

R02 (2nd Floor - Escalators 1 & 2)

Outcome comparisons of four radiation therapy oncology group (RTOG) trials in patients with stage IV-T4 head and neck (H/N) cancer: Encouraging results using intra-arterial (IA) cisplatin (P) and concurrent radiation therapy (RT).
Presenter: Parvesh Kumar, MD
 Poster Number: 19 / Abstract No: 5527

Phase II trial of concurrent split course hyperfractionated radiotherapy (Hfx RT), cisplatin (DDP) and paclitaxel (P) in patients with recurrent, previously irradiated squamous cell carcinoma of the head and neck (SCCHN): Results of RTOG 9911.
Presenter: Corey J. Langer, MD
 Poster Number: 1 / Abstract No: 5509

1:00-5:00 pm 

Health Services Research

(General Poster Session)

Hall A (right half)

Socio-demographic variables influence outcome in Radiation Therapy Oncology Group head and neck trials.
Presenter: Andre A. Konski, MD
 Poster Number: N5 / Abstract No: 6043

Monday, June 07, 2004

8:00-12:00 pm 

Breast Cancer II

Chair: Henry Mark Kuerer, MD, PhD, FRACP; Julie Gralow, MD

(Poster Discussion)

391 (Escalator 7)

A phase II trial of brachytherapy alone following lumpectomy for stage I or II breast cancer: Initial outcomes of RTOG 9517.
Presenter: Robert R. Kuske, MD
 Poster Number: 11 / Abstract No: 565

8:00-12:00 pm 

Genitourinary (Prostate) Cancer

Chair: Robert Reiter, MD; Susan F. Slovin, MD, PhD

(Poster Discussion)

291 (Escalator 7)

A phase II study of external beam radiation therapy combined with permanent source brachytherapy for intermediate risk clinically localized adenocarcinoma of the prostate: Preliminary results of RTOG P-0019.
Presenter: W. Robert Lee, MD
 Poster Number: 18 / Abstract No: 4568

(continued on back cover)